Karyopharm Therapeutics competitors
Karyopharm Therapeutics Competitors include Replimune, Galectin Therapeutics, Pharmacyclics and Stemline Therapeutics.
Add company...
You can compare up to 12 companies. Please remove a company to add a new one
| Save ComparisonClear all |  Karyopharm Therapeutics Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases. |  Galectin Therapeutics Galectin Therapeutics uses galectin science and drug development to create new therapies for fibrotic diseases and cancer. |  Pharmacyclics Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. |  Stemline Therapeutics Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells. | |
Founding Date | Founding Date 2008 | Founding Date 2015 | Founding Date 2001 | Founding Date 1991 | Founding Date 2003 |
Type | Type Subsidiary | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Newton, US HQ München, DE | Locations Milton, GB HQ Woburn, US | Locations Norcross, US HQ | Locations Sunnyvale, US HQ Shanghai, CN Schaffhausen, CH South San Francisco, US | Locations New York, US HQ |
Employees | Employees N/A | Employees N/A | Employees 7 | Employees N/A | Employees 327% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 205.3 m | Valuation ($) N/A | Valuation ($) 329.5 m |
Twitter followers | Twitter followers N/A | Twitter followers N/A | Twitter followers 487 | Twitter followers 840 | Twitter followers N/A |
Financial ⚠ | |||||
Net income | Net income ($129m) (FY, 2017) | Net income (£8.2m) (FY, 2018) | Net income ($16.2m) (FY, 2017) | Net income $86.1m (FY, 2014) | Net income ($67.8m) (FY, 2017) |
Funding | |||||
Total funding raised | Total funding raised $ 248.7m | Total funding raised $ 30m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profileDownload Excel
View company profiles
Replimune
HQ
Milton, GB
Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer.
View companyGalectin Therapeutics
HQ
Norcross, US
Employees
7
Galectin Therapeutics uses galectin science and drug development to create new therapies for fibrotic diseases and cancer.
View companyPharmacyclics
HQ
Sunnyvale, US
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
View companyStemline Therapeutics
HQ
New York, US
Employees
32↑ 7% increase
Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.
View company